Unlocking the potential of
genomic medicine


Download Documentation Aevi Genomics Investor Presentation

Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More >>
Stock Quote
GNMX (Common Stock)
PriceChange% ChangeVolume
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
04/26/17 4:00 p.m. ET
Refresh quote
2016 Annual Meeting Materials

Annual Report to Stockholders
Proxy Statement
Proxy Card

Recent NewsMore >>
04/20/17Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
PHILADELPHIA, PA -- (Marketwired) -- 04/20/17 -- -- Novel genetic mutations predictive of response to AEVI-001 found in approximately 10% of pediatric ADHD patients -- -- New results clarify a path forward for the continued development of AEVI-001 in ADHD patients and potential future development in other neurodevelopmental disorders -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced updated responder data from a subset of genomically identified patients in the SAGA ... 
Printer Friendly Version
04/12/17Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
PHILADELPHIA, PA -- (Marketwired) -- 04/12/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that results identifying a genomic subset of responders from the SAGA trial of AEVI-001 will be presented at the 6th World Congress on ADHD (Attention Deficit Hyperactivity Disorder) taking place April 20-23, 2017 in Vancouver, Canada. In addition, the Company will present findings from a non-interventional phenotype/genotype study of nearly 2,000 children diagnosed with AD... 
Printer Friendly Version
03/30/17Aevi Genomic Medicine to Present at the 16th Annual Needham Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 03/30/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Brian D. Piper, Chief Financial Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 10:00 a.m. EDT at the Westin New York Grand Central Hotel in New York City. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.aevigenomics.com or you may us... 
Printer Friendly Version
Recent PresentationsMore >>
Download Documentation Double-Blind, Placebo-Controlled Study of the Novel Therapeutic AEVI-001 in Adolescents with ADHD and Glutamatergic Network Gene Mutations
Download Documentation Glutamatergic Network Gene Mutations in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Download Documentation SAGA Trial of AEVI-001 Top-line Results Presentation
Download Documentation Aevi Genomics Cowen & Co. 37th Annual Health Care Conference Presentation
Download Documentation Aevi Genomics Investor Day Presentation
Download Documentation JP Morgan 2017 Presentation
Download Documentation Medgenics Inc at the 28th Annual Piper Jaffray Healthcare Conference
Download Documentation Q3 2016 Medgenics Inc Earnings Presentation
Download Documentation Medgenics Poster Presentation at the 63rd Annual American Academy of Child & Adolescent Psychiatry
Download Documentation Q2 2016 Medgenics Inc Earnings Presentation
Download Documentation JMP Life Sciences Conference
Download Documentation Medgenics / Kyowa Hakko Kirin Collaboration for Severe Pediatric Onset Inflammatory Bowel Disease
Download Documentation Medgenics Inc at UBS Global Healthcare Conference Presentation
Download Documentation Q1 2016 Medgenics Inc Earnings Presentation
Download Documentation ASGCT Poster
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.